Akoya Biosciences, Inc. reported its financial results for the first quarter of 2025, showing a decrease in revenue to $16.6 million, down 9.8% from $18.4 million in the same period the previous year. Despite this decline, the company improved its gross margin to 59.3%, up from 45.7%. The company's operating loss for the quarter was reported at $13.4 million, marking a 37.9% improvement compared to a loss of $21.6 million in the prior year period. Operating expenses also saw a reduction, totaling $23.3 million, down 22.3% from $30.0 million. In addition to financial results, Akoya highlighted a significant business development: the selection of its PhenoCycler-Fusion platform for a landmark study funded by Cancer Grand Challenges. This study aims to address cancer inequities through comprehensive spatial analysis and will contribute to the creation of a new Biobank and Data Repository. The company also noted an increase in its installed base, reaching 1,359 instruments by the end of the quarter, a 12.0% rise from the previous year. Publications citing Akoya's technology increased to 1,891, demonstrating a 44.7% year-over-year growth. Akoya is preparing for its impending acquisition by Quanterix Corporation and will not be hosting an earnings conference call or offering forward-looking guidance at this time.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.